Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope.

ABSTRACT: The use of bacteria to specifically migrate to cancerous tissue and elicit an antitumor immune response provides a promising platform against cancer with significantly high potency. With dozens of clinical trials underway, some researchers hold the following views: "humans are nearing the first commercial live bacteria therapeutic." However, the facultative anaerobe Salmonella typhimurium VNP20009, which is particularly safe and shows anticancer effects in preclinical studies, had failed in a phase I clinical trial due to low tumor regression and undesired dose-dependent side effects. This is almost certain to disappoint people's inflated expectations, but it is noted that recent state-of-the-art research has turned attention to bacteria-mediated synergistic cancer therapy (BMSCT). In this

SUBMITTER: Lou X 

PROVIDER: S-EPMC8187705 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature